¼¼°èÀÇ ´ã³¶ Ä¡·á ½ÃÀå
Gallbladder Treatment
»óǰÄÚµå : 1795925
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 472 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´ã³¶ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 48¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 38¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´ã³¶ Ä¡·á ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 4.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 48¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼ö¼úÀº CAGR 5.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾à¹°¿ä¹ý ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 10¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ã³¶ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 10¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 10¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.7%¿Í 3.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ã³¶ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°í±Þ ´ã³¶ Áúȯ °ü¸®¿¡ ´ëÇÑ ¼ö¿ä¸¦ Çü¼ºÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

´ã¼®, ´ã³¶¿°, ´ãµµ ¿îµ¿ ÀÌ»óÁõ°ú °°Àº ´ã³¶ ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î À¯ÇàÇϰí ÀÖÀ¸¸ç, ƯÈ÷ °í·ÉÈ­ »çȸ¿Í °íÁö¹æ ½Ä½À°üÀÌ ¸¹Àº Áö¿ª¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº Á¾Á¾ º¹Åë°ú ¼ÒÈ­±â ÁúȯÀ» À¯¹ßÇϰí, Ä¡·áÇÏÁö ¾ÊÀ¸¸é ´ã°ü °¨¿°À̳ª ÃéÀå¿°°ú °°Àº ÇÕº´ÁõÀ» À¯¹ßÇÕ´Ï´Ù. ¼ÒÈ­±â °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¿µ»ó Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ´ã³¶ ÁúȯÀÇ ¹ß°ßÀ²ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¼ö¼úÀû Ä¡·á¿Í ºñ¼ö¼úÀû Ä¡·á ¸ðµÎ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

º¹°­°æ ´ã³¶ÀýÁ¦¼úÀº Áõ»ó¼º ´ã¼® ¹× ¿°Áõ¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·á¹ýÀÔ´Ï´Ù. ÇÏÁö¸¸, º¸´Ù ÃÖ¼Òħ½ÀÀûÀÎ ½Ã¼ú, Á¶±â ¶Ç´Â ºñÆó»ö¼º Áúȯ¿¡ ´ëÇÑ ¾à¸®ÇÐÀû °³ÀÔ, ¼ö¼ú ÈÄ È¸º¹ ÇÁ·ÎÅäÄÝÀÇ °³¼± µî ½ÃÀåÀº ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê°ú °°Àº ¾à¹° ±â¹Ý Á¢±Ù¹ýÀº ƯÁ¤ ÄÝ·¹½ºÅ×·Ñ °á¼®À» ¿ëÇØÇϰųª °íÀ§Ç豺 ȯÀÚÀÇ °á¼® Çü¼ºÀ» ¿¹¹æÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. Á¶±â Áø´Ü°ú °³º°È­µÈ Ä¡·á°èȹÀº º¸´Ù Ç¥ÀûÈ­µÈ °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí, °á°ú¸¦ °³¼±Çϸç, Àå±âÀûÀÎ ÇÕº´ÁõÀ» °¨¼Ò½Ãŵ´Ï´Ù.

¼ö¼ú°ú ±â¼úÀÇ ¹ßÀüÀº Ä¡·á Àü·«¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?

ÃÖ¼Òħ½À ¼ö¼úÀº ´ã³¶ Ä¡·áÀÇ ÃÖÀü¼±ÀÔ´Ï´Ù. º¹°­°æ ¼ö¼úÀ̳ª ·Îº¿ º¸Á¶ ´ã³¶ ÀýÁ¦¼úÀº ÀÔ¿ø ½Ã°£À» ´ÜÃàÇϰí, Á¶Á÷ ¿Ü»óÀ» ÃÖ¼ÒÈ­Çϸç, °¨¿° À§ÇèÀ» ³·Ãä´Ï´Ù. ¼ö¼ú Áß ´ã°üÁ¶¿µ¼ú ¹× 3D ½Ã°¢È­ µî dzºÎÇÑ ¿µ»ó ½Ã½ºÅÛÀº ´ãµµ ÇØºÎÇÐÀÇ Á¤È®ÇÑ ½Äº°À» Áö¿øÇÏ¿© ¼ö¼ú ÇÕº´ÁõÀ» °¨¼Ò½Ãŵ´Ï´Ù. ¼ö¼ú ¼¾ÅÍ´Â ´ã°ü ¼Õ»óÀ» ÁÙÀ̰í ȯÀÚÀÇ È¸º¹ ±â°£À» ´ÜÃàÇϱâ À§ÇØ Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄÝÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀº ¼ö¼ú Àü Æò°¡¿Í ¼ö¼ú ÈÄ ¸ð´ÏÅ͸µ¿¡µµ ÇѸòÀ» Çϰí ÀÖ½À´Ï´Ù. °íÇØ»óµµ ÃÊÀ½ÆÄ, MRI, °£´ãÃéÀ̹̳ëÀÌÃÊ»ê(HIDA) ½ºÄµÀ» ÅëÇØ ´ã³¶ ±â´É Àå¾Ö¸¦ Á¤È®ÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ 3Â÷ ÀÇ·á¼¾ÅÍ¿¡¼­´Â Áø´Ü ¿öÅ©Ç÷ο쿡 ÀÇ»ç°áÁ¤ Áö¿ø ¼ÒÇÁÆ®¿þ¾î¿Í AI Áö¿ø ¿µ»ó ºÐ¼®ÀÌ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ÀÓ»óÀǰ¡ ȯÀÚ°¡ ¼ö¼ú¿¡ ÀûÇÕÇÑÁö ¶Ç´Â º¸Á¸Àû °ü¸® Àü·«ÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ´ÂÁö¸¦ ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

Àα¸Åë°è ¹× ¿¹¹æ µ¿ÇâÀº ½ÃÀå È®´ë¿¡ ¾î¶² ¿ªÇÒÀ» ÇÒ °ÍÀΰ¡?

´ã³¶ÁúȯÀº ³ëÀÎ, ¿©¼º, ºñ¸¸À̳ª ´ë»çÁõÈıº ȯÀÚ¿¡°Ô¼­ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ À§Çè ¿äÀÎÀÌ Æ¯È÷ µµ½Ã Áö¿ª°ú °í·ÉÈ­ Àα¸¿¡¼­ ´õ ÈçÇØÁü¿¡ µû¶ó ´ã³¶ °ü·Ã Áø´ÜÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °Ç°­ÇÑ ½Ä½À°üÀ» Àå·ÁÇϰí ÄÝ·¹½ºÅ×·ÑÀ» °ü¸®Çϱâ À§ÇÑ ¿¹¹æÀû Ä¡·á ³ë·ÂÀº ÀÌȯÀ² °¨¼Ò¿¡ ÀÏÁ¤ÇÑ ¿ªÇÒÀ» Çϰí ÀÖÁö¸¸, »ýȰ½À°ü°ú °ü·ÃµÈ À§Çè ³ëÃâ·Î ÀÎÇØ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â ¿©ÀüÈ÷ ³ô½À´Ï´Ù.

¿¹¹æÀû ¹× ¼±ÅÃÀû ´ã³¶ ¼ö¼úÀº ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ ¼º¼÷ÇÑ ±¹°¡¿¡¼­´Â ¿Ü·¡¿¡¼­ ½ÃÇàµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ÀÔ¿ø ºñ¿ëÀ» Àý°¨Çϰí ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, ¼ÒÈ­±â °Ç°­¿¡ ´ëÇÑ È¯ÀÚ ±³À° ÇÁ·Î±×·¥Àº Ä¡·á ¼øÀÀµµ¿Í ¼ö¼ú ÈÄ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ °¡Ä¡ ±â¹Ý ÀǷḦ Áß½ÃÇÏ´Â °¡¿îµ¥, Á¶±â ¹ß°ß, ºñħ½ÀÀû ÁßÀç, ¿Ü°úÀû ÇÕº´Áõ °¨¼Ò¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

´ã³¶ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù...

´ã³¶ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ´ã¼®Áõ À¯º´·ü Áõ°¡, º¹°­°æ ¼ö¼ú ¹× ·Îº¿ ¼ö¼úÀÇ »ç¿ë È®´ë, ÷´Ü ¿µ»ó Áø´ÜÀÇ Ã¤Åà Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ­, ºñ¸¸À² Áõ°¡, Áö¹æÀÌ ¸¹Àº ½Ä½À°üÀÌ Àü ¼¼°è Áúº´ ºÎ´ã Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀû ¼ö¼ú ±â¹ýÀÇ ¹ßÀüÀº Áø´Ü Á¤È®µµ Çâ»ó°ú ÇÔ²² Á¶±â °³ÀÔ°ú ȯÀÚ ¿¹ÈÄ °³¼±¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿Ü·¡ ¼ö¼ú ¸ðµ¨°ú ªÀº ȸº¹ ÇÁ·ÎÅäÄÝÀº Ä¡·á¸¦ º¸´Ù Ä£¼÷ÇÏ°í ºñ¿ë È¿À²ÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ´ã¼®ÀÇ ¿ëÇØ¿Í ´ãÁóÀÇ È帧À» Á¶ÀýÇÏ´Â ¾à¹°¿ä¹ýµµ ƯÁ¤ ȯÀڵ鿡°Ô °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡ °ÉÃÄ º¸´Ù ½Å¼ÓÇϰí È¿À²ÀûÀÎ ´ã³¶ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(¼ö¼ú, Åõ¾à, ºñħ½ÀÀû ½Ã¼ú), ÀûÀÀÁõ(´ã³¶¿° ÀûÀÀÁõ, ´ã¼® ÀûÀÀÁõ, ´ãµµ ÀÌ»ó¿îµ¿Áõ ÀûÀÀÁõ), Åõ¿© °æ·Î(°æ±¸ Åõ¿©, ÁÖ»çÁ¦ Åõ¿©, ±¹¼Ò Åõ¿©), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, Àü¹® Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gallbladder Treatment Market to Reach US$4.8 Billion by 2030

The global market for Gallbladder Treatment estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Medication segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 8.0% CAGR

The Gallbladder Treatment market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Gallbladder Treatment Market - Key Trends & Drivers Summarized

What Is Shaping Demand for Advanced Gallbladder Disease Management?

Gallbladder diseases-including gallstones, cholecystitis, and biliary dyskinesia-are prevalent worldwide, particularly in aging populations and regions with high-fat dietary patterns. These conditions often lead to abdominal pain, digestive issues, and, if untreated, complications such as bile duct infection or pancreatitis. Rising awareness about digestive health and improved access to diagnostic imaging are increasing detection rates of gallbladder disorders, prompting greater demand for both surgical and non-surgical treatment options.

Laparoscopic cholecystectomy remains the standard of care for symptomatic gallstones and inflammation. However, the market is evolving to accommodate less invasive techniques, pharmacologic interventions for early-stage or non-obstructive disease, and improved postoperative recovery protocols. Drug-based approaches, such as ursodeoxycholic acid, are used to dissolve certain cholesterol stones or prevent stone formation in high-risk patients. Early diagnosis and personalized treatment planning are enabling more targeted interventions, improving outcomes and reducing long-term complications.

How Are Surgical and Technological Advances Impacting Treatment Strategies?

Minimally invasive surgery is at the forefront of gallbladder treatment. Laparoscopic and robotic-assisted cholecystectomies reduce hospitalization time, minimize tissue trauma, and lower the risk of infection. Enhanced imaging systems-such as intraoperative cholangiography and 3D visualization-support accurate identification of the biliary anatomy, decreasing surgical complications. Surgical centers are adopting standardized protocols to reduce bile duct injuries and shorten patient recovery periods.

Technology also plays a role in preoperative assessment and postoperative monitoring. High-resolution ultrasound, MRI, and hepatobiliary iminodiacetic acid (HIDA) scans enable precise diagnosis of gallbladder dysfunction. Decision-support software and AI-assisted image analysis are emerging in diagnostic workflows, particularly in tertiary care centers. These tools help clinicians determine whether patients are suitable candidates for surgery or can benefit from conservative management strategies.

What Role Do Demographics and Preventive Trends Play in Market Expansion?

Gallbladder conditions are more common in older adults, women, and individuals with obesity or metabolic syndrome. As these risk factors become more prevalent, especially in urban and aging populations, gallbladder-related diagnoses are increasing. Preventive care initiatives aimed at promoting healthier eating habits and managing cholesterol are playing a modest role in reducing incidence, but demand for treatment remains high due to lifestyle-linked risk exposure.

Preventive and elective gallbladder surgeries are increasingly performed in outpatient settings, particularly in countries with mature healthcare infrastructure. This shift reduces hospital stay costs and enhances patient convenience. Additionally, patient education programs on digestive health are improving treatment compliance and postoperative outcomes. As healthcare systems focus on value-based care, more attention is being given to early detection, non-invasive interventions, and reduced surgical complications.

Growth in the Gallbladder Treatment Market Is Driven by Several Factors…

Growth in the gallbladder treatment market is driven by several factors including increasing incidence of gallstone disease, expanded use of laparoscopic and robotic surgeries, and rising adoption of advanced imaging diagnostics. Aging populations, growing obesity rates, and dietary patterns rich in fats contribute to higher disease burden globally. Improvements in minimally invasive surgical techniques, coupled with enhanced diagnostic accuracy, support earlier intervention and better patient outcomes. Outpatient surgical models and shorter recovery protocols make treatment more accessible and cost-effective. Drug therapies for gallstone dissolution and bile flow regulation are also gaining interest for selected patients. Together, these trends are shaping a more responsive and efficient gallbladder care landscape across healthcare systems.

SCOPE OF STUDY:

The report analyzes the Gallbladder Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Surgery, Medication, Non-Invasive Procedures); Indication (Cholecystitis Indication, Gallstones Indication, Biliary Dyskinesia Indication); Administration Route (Oral Administration, Injectable Administration, Topical Administration); End-User (Hospitals End-User, Specialty Clinics End-User, Ambulatory Surgical Centers End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â